Loading video…

The Missed Signals of Adult Cholestasis

Uncover the unspoken symptoms of adult cholestatic liver disease and new insights that reveal their impact on patients’ lives.

References

  1. Bertolini A, Fiorotto R, Strazzabosco M. Bile acids and their receptors: modulators and therapeutic targets in liver inflammation. Semin Immunopathol. 2022;44(4):547-564. doi:10.1007/s00281-022-00935-7 
  2. Jin XY, Khan TM. Quality of life among patients suffering from cholestatic liver disease-induced pruritus: A systematic review. J Formos Med Assoc. 2016;115(9):689-702. doi:10.1016/j.jfma.2016.05.006
  3. Hof WFJ, de Boer JF, Verkade HJ. Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials. Expert Opin Emerg Drugs. 2024;29(3):305-320. doi:10.1080/14728214.2024.2336986
  4. Spinner NB, Loomes KM, Krantz ID, Gilbert MA. Alagille syndrome. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, eds. GeneReviews®. Seattle (WA): University of Washington, Seattle; May 19, 2000.
  5. Cai S-Y, Li M, Boyer JL. The role of bile acid-mediated inflammation in cholestatic liver injury. In: Arias IM, Alter HJ, Boyer JL, Cohen DE, Shafritz DA, Thorgeirsson SS, Wolkoff AW, eds. The Liver. Wiley; 2021.
  6. Marcus E, Stone P, Krooupa A-M, Thorburn D, Vivat B. Quality of life in primary sclerosing cholangitis: a systematic review. Health Qual Life Outcomes. 2021;19(1):100. doi:10.1186/s12955-021-01739-3
  7. Bowlus CL, Arrivé L, Bergquist A, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023;77(2):659-702. doi:10.1002/hep.32771
  8. Onofrio FQ, Hirschfield GM, Gulamhusein AF. A practical review of primary biliary cholangitis for the gastroenterologist. Gastroenterol Hepatol (NY). 2019;15(3):145-154.
  9. Shamshtein D, Liwinski T. Pathogenesis and management of fatigue in primary biliary cholangitis, Fatigue: Biomedicine, Health & Behavior, 2022;10(1):1-25. doi:10.1080/21641846.2022.2034473
  10. Mayo MJ, Carey E, Smith HT, et al; TARGET-PBC Investigators. Impact of pruritus on quality of life and current treatment patterns in patients with primary biliary cholangitis. Dig Dis Sci. 2023;68(3):995-1005. doi:10.1007/s10620-022-07581-x
  11. Isley S, Johnson E, Swain MG, Tandon P. Fatigue in cholestatic liver disease: a review of mechanisms and non-pharmacologcal management. Curr Hepatol Rep. 2025 Oct 20;24(1):31.
  12. Pollock G, Minuk GY. Diagnostic considerations for cholestatic liver disease. J Gastroenterol Hepatol. 2017;32(7):1303-1309. doi:10.1111/jgh.13738
  13. Onofrio FQ, Hirschfield GM. The pathophysiology of cholestasis and its relevance to clinical practice. Clin Liver Dis (Hoboken). 2020;15(3):110-114. doi:10.1002/cld.894
  14. Data on file. Mirum Pharmaceuticals, Inc.
  15. Dean R, Yazdanfar M, Zepeda J, et al. Treatment of pruritus in primary sclerosing cholangitis: analysis of the consortium for autoimmune liver disease registry. Hepatol Commun. 2025;9(5):e0703. doi:10.1097/HC9.0000000000000703
  16. Kowdley KV, Safer R, Gomel R, et al. A multinational survey assessing the impact and burden of pruritus on patients with primary sclerosing cholangitis. Hepatol Commun. 2026;10(3):e00904. doi:10.1097/HC9.0000000000000904
  17. Vander Does A, Levy C, Yosipovitch G. Cholestatic itch: our current understanding of pathophysiology and treatments. Am J Clin Dermatol. 2022;23(5):647-659. doi:10.1007/s40257-022-00710-2
  18. Wang W-L, Lian H, Liang Y, Ye Y, Tam PKH, Chen Y. Molecular mechanisms of fibrosis in cholestatic liver diseases and regenerative medicine-based therapies. Cells. 2024;13(23):1997. doi:10.3390/cells13231997
  19. Iluz-Freundlich D, Zhang M, Uhanova J, Minuk GY. The relative expression of hepatocellular and cholestatic liver enzymes in adult patients with liver disease. Ann Hepatol. 2020;19(2):204-208. doi:10.1016/j.aohep.2019.08.004
  20. Cai S-Y, Boyer JL. The role of bile acids in cholestatic liver injury. Ann Transl Med. 2021;9(8):737. doi:10.21037/atm-20-5110
  21. Zeng J, Fan J, Zhou H. Bile acid-mediated signaling in cholestatic liver diseases. Cell Biosci. 2023;13(1):77. doi:10.1186/s13578-023-01035-1
  22. Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis - a comprehensive review. J Hepatol. 2017;67(6):1298-1323. doi:10.1016/j.jhep.2017.07.022
  23. Vitale G, Sciveres M, Mandato C, d'Adamo AP, Di Giorgio A. Genotypes and different clinical variants between children and adults in progressive familial intrahepatic cholestasis: a state-of-the-art review. Orphanet J Rare Dis. 2025;20(1):80. doi:10.1186/s13023-025-03599-2
  24. Thompson RJ, Vilarinho S, Miquel R, Keitel V. Challenges in the diagnosis and treatment of genetic cholestasis in adults. JHEP Rep. 2025;8(1):101625. doi:10.1016/j.jhepr.2025.101625

Watch next

Adult-onset PFIC

Evolving Understanding of PFIC

Dr Richard Thompson
Dr Robert Gish

3 min

Adult-onset PFIC

PFIC Overview: Chronic Cholestasis and Diagnostic Clues

Dr Richard Thompson
Dr Robert Gish

3 min

Adult-onset PFIC

Serious Consequences of Undiagnosed PFIC

Dr Richard Thompson
Dr Robert Gish

3 min